Drug Profile


Alternative Names: NSC B116209; OK 432; PCB 45

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Adjuvants; Antineoplastics; Biological factors
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Lung cancer; Lymphangioma; Malignant ascites

Most Recent Events

  • 31 Oct 2002 Chugai Pharmaceutical has been acquired by Roche
  • 15 Oct 2002 A study has been added to the Cancer therapeutic trials section
  • 08 Aug 2001 Launched for Cancer in Taiwan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top